| 5/9/2016 | PP | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
| 4/13/2016 | PP | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
| 4/12/2016 | PP | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
| 4/8/2016 | PP | Market Commentary: Depomed surges after activist letter to the board; Yahoo! richens on deal chatter
|
| 4/7/2016 | PP | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
| 1/11/2016 | PP | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
| 10/23/2015 | PP | Market Commentary: Huron slides outright, ‘comes in’ on swap on disappointing earnings; Horizon rebounds
|
| 9/22/2015 | PP | Market Commentary: Convertibles, broader markets drop; Weatherford deal pulled, stock rebounds; biotechs down
|
| 7/20/2015 | PP | Market Commentary: Exelixis jumps outright, expands on hedge on positive trial data; Depomed better on hedge
|
| 7/7/2015 | PP | Market Commentary: Medicines higher in active trade; Depomed deflects Horizon offer; Ctrip off its lows
|
| 5/12/2015 | PP | Market Commentary: Planned SunEdison seen cheap; existing SunEdisons finish unchanged; Depomed drops outright
|
| 3/13/2015 | PP | Market Commentary: FXCM bumps up on positive earnings; Herbalife adds outright, unchanged dollar neutral
|
| 9/5/2014 | PP | Market Commentary: New Huron Consulting trades at par; Depomed shares push higher after court decision
|
| 9/4/2014 | PP | Market Commentary: New Clovis, Depomed upsized, add on debut; Electronics For Imaging edges up; Teslas mixed
|
| 9/3/2014 | PP | Market Commentary: Planned Depomed, Electronics For Imaging add in the gray; Huron Consulting notes on tap
|
| 9/2/2014 | PP | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|
| 4/24/2007 | PP | Market Commentary: Halozyme secures $32.09 million from private placement; Adaltis plans C$28 million stock offering
|
| 4/23/2007 | PP | New Issue: Depomed closes $20 million direct placement
|
| 4/23/2007 | PP | Market Commentary: Depomed seals $20 million direct placement of stock; Arbios raises $4.8 million
|
| 12/12/2006 | PP | Market Commentary: Depomed seals $30 million equity line; HemoSense wraps $6.99 million stock sale
|
| 12/12/2006 | PP | New Issue: Depomed receives $30 million equity line
|
| 1/7/2005 | PP | New Issue: Depomed plans direct placement of stock for $22.7 million
|
| 1/7/2005 | PP | Market Commentary: Private placement volume improves slightly; Depomed plans $22.7 million offering
|
| 12/14/2004 | PP | Depomed, Kings Road resolve dispute over series A preferreds
|
